ACS medicinal chemistry letters

Improving new psychedelic treatments by targeting specific brain receptors with precise inhaled doses and better 5-MeO-DMT use methods

Psychedelic Science Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Recent patent applications include innovations such as selective 5-HT2A receptor activators and precision aerosol delivery technologies for psychedelic compounds.

  • Selective 5-HT2A receptor activators may enhance the therapeutic effects of psychedelics.
  • Aerosol delivery technologies could improve the administration of psychedelic compounds.
  • Structured treatment regimens using 5-MeO-DMT are being explored for their potential in treating depression.
  • These developments suggest a shift towards scalable and safer neuropsychiatric therapies.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Dec '25
Developing improved psychedelic treatments by targeting serotonin and controlling drug timing
top 30% journal
editorial
Jan '25
Advantages and Challenges of Very Fast-Acting Psychedelics for Treating Depression
top 1% journal
cited by 25 papers
journal article
May '24
Structure and treatment potential of 5-methoxytryptamines
cited by 69 papers
journal article
Jan '16
Behavior and body processing interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine
top 20% journal
cited by 32 papers
research support, n.i.h., extramural
Jan '26
Safety and Brain Activity of a Short-Acting Serotonin-Related Psychedelic in Beagle Dogs
top 50% journal
journal article
Jan '26
New Developments in Psychedelic Treatments: Modified Iboga Compounds, Brainwave-Guided Psilocybin Dosing, and Improved Harmine-DMT Combinations
top 30% journal
editorial
Dec '24
Serotonin 1A Receptors Influence Behavioral Responses to Serotonin 2A Receptor Activation by 5-MeO-DMT-Like Compounds in Mice
top 20% journal
cited by 10 papers
research support, n.i.h., extramural

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the psychedelic science brief

issue #53
One psilocybin session held antidepressant effects for 52 weeks in a new follow-up study
2 weeks ago7 studies
issue #52
Psilocybin didn't create disorder in the brain — it created a different kind of order
3 weeks ago7 studies
issue #51
Psilocybin worked for treatment-resistant depression in real Swiss clinics — not just controlled trials
4 weeks ago7 studies
issue #50
Psilocybin beat placebo on depression scores in an NHS trial — by a lot
5 weeks ago7 studies
issue #49
Psilocybin stays active in neurons long after it leaves the bloodstream — here's what that means
6 weeks ago7 studies
issue #48
Psychedelics during adolescence reshaped adult social behavior in rats — here's the circuit
7 weeks ago7 studies
issue #47
Psilocybin rewired prefrontal circuits in mice — but only for one specific type of cognitive failure
8 weeks ago7 studies
issue #46
Psilocybin cut two specific brain chemicals in depressed patients — here's what that means
9 weeks ago7 studies
issue #44
Psilocybin rewires brain feedback circuits for weeks after a single dose, new evidence shows
10 weeks ago7 studies
issue #43
A pill form of ketamine cut dissociation to near-zero vs. nasal spray's 29.6-point spike — but missed its main antidepressant target
11 weeks ago7 studies
explore the archive
See more issues from the psychedelic science brief